NICE recommends AstraZeneca's Imfinzi for adults with non-small cell lung cancer - PMLiVE

The treatment will be available for eligible patients in England with a stage 3 diagnosis

AstraZeneca (AZ) has announced that the National Institute for Health and Care Excellence (NICE) has approved the routine use of Imfinzi (durvalumab) within NHS England as a monotherapy to treat loca… [+2373 chars]

full article...